2023
Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study
Najjar-Debbiny R, Barnett-Griness O, Khoury J, Gronich N, Weber G, Adir Y, Shteinberg M, Shneir S, Sharma L, Saliba W. Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study. The American Journal Of Medicine 2023, 136: 1087-1093.e2. PMID: 37598922, DOI: 10.1016/j.amjmed.2023.07.020.Peer-Reviewed Original ResearchPulmonary fibrosisCase-control studyCOVID-19 severityCOVID-19Multivariable conditional logistic regression modelsNested Case-Control StudyConditional logistic regression modelsSevere COVID-19Prior COVID-19COVID-19 infectionLogistic regression modelsLargest healthcare providerUnderlying cohortCohort entrySignificant morbiditySurveillance biasOdds ratioSevere diseaseFibrosisHealthcare providersCoronavirus diseaseCalendar timePatientsCohortLag time
2021
Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators
Schwarz B, Sharma L, Roberts L, Peng X, Bermejo S, Leighton I, Casanovas-Massana A, Minasyan M, Farhadian S, Ko AI, Team Y, Dela Cruz CS, Bosio CM. Cutting Edge: Severe SARS-CoV-2 Infection in Humans Is Defined by a Shift in the Serum Lipidome, Resulting in Dysregulation of Eicosanoid Immune Mediators. The Journal Of Immunology 2021, 206: ji2001025. PMID: 33277388, PMCID: PMC7962598, DOI: 10.4049/jimmunol.2001025.Peer-Reviewed Original ResearchConceptsLipid mediatorsRisk factorsSevere diseaseSevere SARS-CoV-2 infectionHospitalized COVID-19 patientsSARS-CoV-2 infectionImportant immune regulatory roleSevere COVID-19COVID-19 patientsImmune regulatory roleProinflammatory lipid mediatorsCOVID-19Immunomodulatory eicosanoidsImmune mediatorsSerum lipidomeAdvanced agePatientsCOVID-19 pandemicCytochrome P450MortalityDiseaseDysregulationMediatorsLMS productsLipidome
2020
The kinetics of humoral response and its relationship with the disease severity in COVID-19
Ren L, Zhang L, Chang D, Wang J, Hu Y, Chen H, Guo L, Wu C, Wang C, Wang Y, Wang Y, Wang G, Yang S, Dela Cruz CS, Sharma L, Wang L, Zhang D, Wang J. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Communications Biology 2020, 3: 780. PMID: 33311543, PMCID: PMC7733479, DOI: 10.1038/s42003-020-01526-8.Peer-Reviewed Original ResearchConceptsHumoral responseDisease severityReceptor-binding domainAntibody titersSpike proteinSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2COVID-19Respiratory syndrome coronavirus 2Titers of NAbsGeometric mean titersCOVID-19 patientsSyndrome coronavirus 2Coronavirus disease 2019Disease courseMean titersCoronavirus 2Antibody responseIgG antibodiesRisk factorsIg levelsImmunoglobulin ADisease 2019Severe casesModerate infectionsDoes inflammation help during COVID-19?
Sharma L, Chang D, Dela Cruz CS. Does inflammation help during COVID-19? ERJ Open Research 2020, 6: 00557-2020. PMID: 33083436, PMCID: PMC7553107, DOI: 10.1183/23120541.00557-2020.Peer-Reviewed Original ResearchRapid decline of seasonal influenza during the outbreak of COVID-19
Young G, Peng X, Rebaza A, Bermejo S, De C, Sharma L, Dela Cruz CS. Rapid decline of seasonal influenza during the outbreak of COVID-19. ERJ Open Research 2020, 6: 00296-2020. PMID: 32832527, PMCID: PMC7430143, DOI: 10.1183/23120541.00296-2020.Peer-Reviewed Original ResearchPersistent Viral Presence Determines the Clinical Course of the Disease in COVID-19
Chang D, Zhao P, Zhang D, Dong JH, Xu Z, Yang G, Li BY, Liu HX, Li BA, Qin CF, Peng XH, Wang FS, Xie LX, Chen Z, Dela Cruz CS, Sharma L, Qin EQ. Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 2585-2591.e1. PMID: 32574840, PMCID: PMC7305869, DOI: 10.1016/j.jaip.2020.06.015.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBetacoronavirusChildChild, PreschoolComorbidityCoronavirus InfectionsCOVID-19C-Reactive ProteinFemaleGlucocorticoidsHumansInfantInflammationInflammation MediatorsInterleukin-6MaleMiddle AgedPandemicsPneumonia, ViralReal-Time Polymerase Chain ReactionRespiration, ArtificialSARS-CoV-2Severity of Illness IndexYoung AdultConceptsDisease severityViral clearanceViral persistenceDisease outcomeCOVID-19Viral presenceExtensive lung involvementC-reactive proteinEffective antiviral therapyCoronavirus disease 2019Severe disease outcomesHost antiviral mechanismsInfectious viral particlesImmunomodulatory therapyInflammatory markersLung involvementRespiratory supportClinical courseAntiviral therapyIL-6Viral reactivationClinical managementInflammatory responseChest imagingDisease 2019Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang Q, Xu S, Zhu H, Xu Y, Jin Q, Sharma L, Wang L, Wang J. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clinical Infectious Diseases 2020, 71: 778-785. PMID: 32198501, PMCID: PMC7184472, DOI: 10.1093/cid/ciaa310.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Humoral responseSymptom onsetIgM ELISAProbable casesEarly humoral responseHost humoral responseMajor healthcare threatCoronavirus disease 2019IgA antibody detectionCOVID-19Viral nucleic acidsQuantitative polymerase chain reactionNovel coronavirus diseaseFalse-negative resultsMedian durationAntibody testingIgG responsesIgM antibodiesInfected patientsPolymerase chain reactionPositive rateDisease 2019Healthcare threatSubclinical cases